NCT00331409View on ClinicalTrials.gov

Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Kidney Cancer
Interventions
DRUG

Everolimus

2.5 mg by mouth daily

DRUG

imatinib mesylate

600 mg by mouth daily

Trial Locations (1)

97239-3098

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

OHSU Knight Cancer Institute

OTHER

NCT00331409 - Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer | Biotech Hunter | Biotech Hunter